Clinical Trial Detail

NCT ID NCT02595905
Title Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors National Cancer Institute (NCI)

breast cancer



Cisplatin + Veliparib

Age Groups: senior adult

Additional content available in CKB BOOST